Why Eco Animal Health Group Plc is set to outperform AstraZeneca plc in 2017

Eco Animal Health Group Plc (LON: EAH) has more appeal than AstraZeneca plc (LON: EAH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today’s results from Eco Animal Health (LSE: EAH) show that the healthcare company is making excellent progress. They also indicate that it has the potential to continue to make share price gains following its 69% rise of the last year. This is well ahead of sector peer AstraZeneca (LSE: AZN) with a 3% fall during the same timeframe. Looking ahead to 2017, this outperformance could continue.

Strong growth

Eco Animal Health’s first half report shows that its current strategy is working well. Revenue has increased by 25%, while pre-tax profit is up 97% versus the same period of the previous year.

There was strong performance in the US and China, with demand for Aivlosin still strong. This caused a rise in its sales of 15%, while EU Aivlosin approval allowed the submission of regulatory filings for key global egg producing markets. And with heavy invest investment in R&D, Eco Animal Health is well positioned to deliver further growth over the medium term.

Encouragingly, cash generation continues to be strong, with the company now having a net cash position of £18.5m. This provides it with the financial flexibility to not only survive during potentially challenging periods, but to also invest in future growth or even in M&A opportunities.

In fact, in the current year Eco Animal Health is forecast to record a rise in its earnings of 34%, followed by growth of 17% next year. This puts it on a price-to-earnings growth (PEG) ratio of 1.9, which indicates that its shares could move higher.

A challenging period

The performance of Eco Animal Health contrasts with that of AstraZeneca. The latter is continuing to endure a difficult period, with a loss of patents on key, blockbuster drugs hurting its financial performance. Although an aggressive acquisition programme has slowed the decline in its bottom line, in the current year AstraZeneca is still expected to report a marginal fall in earnings, followed by a slump of 9% next year.

As such, it’s relatively likely that Eco Animal Health will outperform its larger peer in 2017. It has superior growth prospects and investor sentiment is therefore likely to improve more rapidly than for AstraZeneca.

Outlook

Despite this, AstraZeneca remains a sound long-term buy. Its acquisition programme should deliver positive bottom line growth over the medium term, while its price-to-earnings (P/E) ratio of 12.5 indicates that it offers excellent value for money. It could therefore begin to be rated upwards by the market as its financial performance begins to improve in future years.

In addition, with it having a yield of 5.2% which is covered 1.5 times by profit, it remains a sound income play. Certainly, it’s superior in a dividend sense to Eco Animal Health, which yields 1.2% from a dividend covered 2.1 times by profit. However, regarding which stock will rise by the greatest amount in 2017, Eco Animal Health seems to be the stronger of the two.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and ECO Animal Health Group. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »